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Chapter 6 
A peripheral 5-HTID-like receptor involved in 
serotonergic induced hindlimb scratching in rats 
European Journal of Pharmacology (1991) 194,201 - 208. 
SUMMARY 
The pharmacological characteristics of hindlimb scratching induced by 
serotonergic compounds were studied. We conclude that hindlimb scratching induced by 
serotonergic compounds is mediated by a serotoninlD (5-HTID) or 5-HTID-like receptor 
outside the blood-brain barrier because hindlimb scratching could be induced by s.c. 
injection of 5-methoxytryptamine (5-MeOT), 5-carboxamidotryptamine (5-CT), 
bufotenine, 5-hydroxytryptamine (5-HT) and tryptamine. These compounds have high 
affinity for 5-HTIA and 5-HTlD receptors. The 5-HTIA receptor agonist 8-hydroxy- 
2-(di-n-propy1amino)-tetralin (8-OH-DPAT), the 5-HTIC receptor agonist MK 212, and 
the mixed 5-HTlc/5-HT2 receptor agonists (dl)-1-(2,5 dimethoxy-4-iodopheny1)- 
2-aminopropane (DOI) and quipazine did not induce hindlimb scratching. Rather, the 
latter compounds attenuated 5-MeOT induced hindlimb scratching. The 5-HT releasing 
compounds fenflurarnine and p-chloroamphetamine (PCA) inhibited whereas the 5-HT 
re-uptake inhibitors fluvoxamine and indalpine potentiated 5-MeOT-induced hindlimb 
scratching. 5-MeOT-induced hindlimb scratching could be inhibited dose dependently 
by the a*-adrenoceptor blockers yohimbine and rauwolscine, which also have high 
affinity for 5-HTlD receptors, whereas the q-adrenoceptor blocker piperoxan only 
weakly counteracted hindlimb scratching. Haloperidol, apomorphine, morphine, 
clonidine and methiothepin strongly attenuated hindlimb scratching, atropine, naloxone 
and ICS 205930 attenuated it weakly whereas domperidone, methylatropine and 
mepyramine were inactive in doses up to 10 mglkg. Hindlimb scratching induced by 
5-MeOT was potentiated by the 5-HT receptor antagonists metergoline, methysergide, 
mesulergine, mianserin, ritanserin and xylamidine. Hindlimb scratching was not 
induced by i.c.v. injection of 5-MeOT. This lack of i.c.v. activity of 5-MeOT and the 
effect of xylamidine suggests that the site of action for induction of hindlimb scratching 
is outside the blood-brain barrier. 
6.1 INTRODUCTION 
Hindlimb scratching or reciprocal hindlimb scratching in mice has been described 
after intraperitoneal administration of mescaline and some related dimethoxy 
amphetamines (Kulkarni, 1973), intracranial injection of substance P and somatostatin 
(Dobry et al., 1981), intracerebroventricular (i.c.v.) injection of neurohypophyseal 
hormones (Meisenberg, 1981; 1982) or after intrathecal administration of pilocarpine 
(Scott et al., 1987). In rats, scratching behaviour has been observed after i.c.v. injection 
of bombesin, bombesin-like peptides, somatostatin and substance P (Van Wimersma 
Greidanus et al., 1985; 1987; Negri, 1986; Van Wimersma Greidanus and Maigret, 
1988). Recently we noticed that rats showed excessive hindlimb scratching after 
subcutaneous injection of 5-methoxytryptamine (5-MeOT). 5-MeOT has high affinity 
for 5-HT receptors (Hoyer, 1989). It is thus possible that this 5-MeOT-induced hindlimb 
scratching is mediated by serotonergic receptors. It is generally accepted that the 5-HT 
receptor population can be divided into 5-HT1 and 5-HT2 receptor subpopulations on 
the basis of their affinity for 5-HT and spiperone, respectively (Peroutka and Snyder, 
1979). The 5-FIT1 receptors can be subdivided further into 5-HTIA, 5-HTIB, 5-HTIC 
and 5-HTID receptor subtypes (Pedigo et al., 1981; Schnellmann et al., 1984; Pazos et 
al., 1984; Heuring and Peroutka, 1987; Waeber et al., 1988 a,b; Hoyer et al., 1988). It 
has been possible to ascribe a number of symptoms of the 5-HT syndrome to selective 
activation of one of these 5-HT receptor subtypes. There is evidence to suggest that 
selective activation of 5-HTIA receptors results in the appearance of lower lip retraction 
(Berendsen et al., 1989), selective activation of 5-HTlc receptors results in the 
appearance of penile erection (Berendsen et al., 1990) and activation of the 5-HT2 
receptors results in the appearance of head shakes (Yap and Taylor, 1983). If hindlimb 
scratching induced by 5-MeOT is mediated by a serotonergic mechanism, it is of 
interest to know which 5-HT receptor subtype(s) might be involved. 
In this study we describe the results of a series of experiments showing that 
5-HTID or 5-HTID-like receptors might be involved in drug induced hindlimb 
scratching after systemic administration. 
6.2 MATERIALS AND METHODS 
6.2.1 Animals 
Naive male wistar rats (Cpb:WU, Harlan Sprague Dawley, Zeist, The 
Netherlands) weighing 140 - 200 g were used. The animals were housed in white PVC 
cages (40x40~18 cm) with a wire mesh lid, 5 animals per cage, under a controlled 12 h 
light-dark cycle, with lights on at 6.00 a.m. The rats were allowed free access to 
standard food pellets and tap water. 
6.2.2 Procedure 
All experiments were performed between 9.30 and 14.30 h in a quiet experimental 
room. Ten animals were scored at the same time, and each treatment group was equally 
represented in each observation run. Successive runs were performed until the results of 
8 animals per treatment were obtained. Treatments were randomized over the animals 
within a run. After injection of an agonist, the rats were placed in small perspex 
observation cages (7 .5~18~30  cm). A mirror was placed behind these cages to allow all- 
round observation of the rats. 
1.c.v. injections of 5-MeOT were made via guide cannulas (diameter 0.3 mm) into 
the right lateral ventricle. The cannulas were placed at least one week before the test. 
The rats were anaesthetised with sodium pentobarbital (60 mgkg i.p.) and placed in a 
stereotaxic frame. The cannulas were placed at the coordinates 0.8 mm posterior to the 
bregma, 1.5 mm lateral to the midline and 3 mm below the dorsal surface of the skull 
according to the the atlas of Paxinos and Watson (1986). The injection needle was 1 mm 
longer than the guide cannula. Hindlimb scratching was scored from 5 till 30 min after 
agonist treatment by scoring the presence or absence of scratching every 30 s; with this 
time sampling method the maximum score was 5 1. For the time response curve for 
5-MeOT-induced scratching, the rats were injected with 5-MeOT 1 or 5 mglkg and 
observed from 5 till 30, 35 till 60, 65 till 90 and from 95 till 120 min after injection. 
In the interaction studies 5 mgkg s.c. of 5-MeOT was used to induce scratching. 
The direct 5-HT agonists were injected simultaneously with 5-MeOT whereas the other 
compounds were injected s.c. 30 min before 5-MeOT. 
6.2.3 DRUGS AND SOLUTIONS 
The following drugs were used: apomorphine HCl (O.P.G., the Netherlands); 
atropine sulphate (Nogepha); atropine methylbromide and bufotenine from Sigma; 
clonidine HC1 (synthetised in the chemical Research & Development Laboratories of 
Organon); 5-carboxamidotryptamine (5-CT), (dl)-1-(2,5 dimethoxy-4-iodopheny1)- 
2-aminopropane HC1 (DOI) and 8-hydroxy-2-(di-n-propy1amino)tetralin HBr (8-OH- 
DPAT) from Research Biochemicals Inc. (RBI); domperidone (MotiliumR) and 
haloperidol (HaldolR) from Janssen Pharmaceuticals; fenfluramine HCl (Servier); 
5-hydroxytryptarnine methane sulfonate (5-HT; Merck); indalpine (Pharmuka); 
methysergide maleate and 3-tropanyl-indole-3-carboxylate (ICS 205930; Sandoz); 
mepyramine HCl (Societt Parisienne d' Expansion Chimique); metergoline 
(Farmitalia); 5-methoxytryptamine (5-MeOT; Aldrich); metoprolol tartrate (Hassle); 
mianserin HCl (Organon International); 2 chloro-6-(1- piperazinyl) pyrazine monohydro 
chloride (MK 212; Merck, Sharpe and Dohme); quipazine maleate (Miles Laboratories); 
rauwolscine (Carl Roth); tryptamine HC1 (Fluka); yohimbine HC1 (ACF Chemie Farma) 
and xylamidine tosylate (Wellcome Research Laboratories). 
Haloperidol was diluted from 5 mgkg HaldolR ampoules to the required 
concentrations in sterile saline. Apomorphine was dissolved in saline containing 0.5 mg 
of ascorbic acid and 0.5 mg of mannitol per mg of apomorphine. Metergoline, 
domperidone and xylamidine were suspended in an aqueous solution of 5% Mulgofen 
(EL 719R, GAF Corp.) and 0.9% NaCl. All other drugs were dissolved in sterile saline 
solution. All drug solutions or suspensions were freshly prepared and were injected s.c. 
into the loose skin at the back of the neck. 
A volume of 5 mllkg body weight was used. Control animals received an 
equivalent volume of vehicle. When drug solutions were made up from the salt of the 
compound, the doses refer to the weight of the salt. 
6.2.4 STATISTICS 
The results are expressed as the mean score per group + S.E.M. The statistical 
significance of the drug effects was determined with the Kruskal-Wallis ANOVA 
followed by the Mann-Whitney U-test in the interaction studies. IDs0 values were 
calculated by the linear regression analysis according to the method of Litchfield and 
Wilcoxon (1 949). 
6.3 RESULTS 
6.3.1 Induction of hindlimb scratching 
Untreated, or placebo treated rats placed in the observation cages used in these 
experiments hardly scratched, the highest score reached during the 25 min observation 
period was 3.0 + 0.5. However, within a few minutes after subcutaneous injection of 
5-MeOT the rats started to make scratching movements with their hindlimbs. 
Scratching 
score 
Periods of 12.5 min each 
Figure 1: Time-response curve for 5-MeOT induced scratcing. Scratching behaviour was scored 
during 25 min of each half hour, i.e., from 5 - 30 min, 35 - 60 min, 65 - 90 min and from 95 - 120 
min after 5-MeOT injection. These 25 min were divided in 2 periods of 12.5 min, and the mean 
scores of these periods f. S.E.M. are plotted in the fig. Eight animals per group were used. 
A - A placebo; - 5-MeOT 1 mglkg; 0 ---- 0 5-MeOT 5 mgkg. 
Table 1. Induction of hindlimb scratching. Hindlimb scratching was scored from 5 till 30 min 
after S.C. injection of the compounds by using a time sampling method. Eight animals per group 
were observed. 
Drug Dose Mean hindlimb 
mg/kg s.c. scratching 












P < 0.001 
The maximal response was reached after about 30 min, while the duration of the 
response depended on the dose given (fig. 1). The skin or fur is not always touched 
during these scratching movements, and this is termed hindlimb scratching. Hindlimb 
scratching was measured from 5 till 30 min after 5-MeOT treatment in all interaction 
studies. 5-MeOT induced hindlimb scratching in a dose-dependent manner, 0.1 mgkg 
being inactive and 0.22 mglkg inducing a small but significant (Pc0.05) increase in 
scratching (table 1). Subcutaneous injection of 5-CT, bufotenine, serotonine and 
Scratching 
score 
1 Yohimbine Rauwolscine Piperoxan 
0 1.0 2.2 4.6 10.0 0 2.2 4.6 10.0 22.0 0 1.0 2.2 4.6 10.0 
Dose (mglkg) 
Figure 2: Effect of yohimbine, rauwolscine and piperoxan on 5-MeOT (5 mg/kg)-induced 
hindlimb scratching. The columns represent the mean scratching scores of 8 animals, as measured 
from 5 till 3 0  min after 5-MeOT treatment. The compounds were injected 30 min before 5-MeOT. 
The vertical bars represent the S.E.M. 
* p<o.os; ** P<O.Ol; *** P<O.OOl 
tryptamine also induced hindlimb scratching (table 1). The response to 5-CT was dose- 
dependent and a mean score + S.E.M. of 3 1.4 + 2.9 was reached after 2.2 mgkg. At 0.1 
mglkg, 5-CT hardly induced hindlimb scratching whereas at 0.22 mgkg marked 
hindlimb scratching was seen. A maximum score of 26.8 + 2.0 was reached with 4.6 
mgkg  bufotonine and then the response levelled off. 
The scores for serotonin and tryptamine were much lower. After serotonin 2.2 mgkg a 
score of 19.8 + 1.6 and after tryptamine (46 mg/kg) a score of 14.6 + 2.5 was reached; 
doses up to 4.6 rngkg tryptamine hardly induced hindlimb scratching. The dose- 
response curve for serotonin had an inverted U shape with a peak effect after 2.2 mgkg. 
Hindlimb scratching was not seen after i.c.v. injection of 5-MeOT in doses up to 100 
pglrat. No other compound used in this study induced hindlimb scratching. Besides 
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Dose (mglkg) Dose (rnglkg) 
Figure 3: The effect of some indirect 5-HT agonists on 5-MeOT (5 mg1k.g)-induced hindlimb 
scratching. A: 5-HT releasing compounds, B: 5-HT reuptake inhibitors. The mean scratching 
scores from 8 animals per group, measured from 5 till 30 min after 5-MeOT treatment, are given. 
The compounds were injected 30 min before 5-MeOT. The vertical bars represent the S.E.M. 
* P<O.O5; ** P<O.Ol ; *** P<O.OOl 
Table 2. 
Effect of a variety of compounds on 5-MeOT (5 mglkg s.c.)-induced hindlimb scratching. IDs0 
values are given. Hindlimb scratching was scored from 5 till 30 min after 5-MeOT injection. 
Pretreatment times are given in parentheses; all drugs were s.c. injected in groups of 8 animals. 
























inactive up to 10 mg/kg 
inactive up to 10 mg/kg 
inactive up to 10 mg/kg 
Table 3. Effect of 5-HT antagonists on 5-MeOT (5 mgkg s.c.)-induced hindlimb scratching. 
Compounds were injected 30 min before 5-MeOT 
Drug Dose Mean hindlimb scratching 































a~ < 0.05; b~ < 0.01; 'P < 0.001 compared to control group 
treated rats showed flat body posture, hypoactivity and cyanosis. Tryptamine-treated 
rats showed slight ptosis. 
6.3.2 Antagonism of 5-MeOT-induced hindlimb scratching 
A dose of 5 mgtkg of 5-MeOT was used for the interaction studies. Scratching 
scores after this dose varied between a mean + S.E.M. of 22.1 + 2.7 and 31.4 + 1.8. 
Hindlimb scratching induced by 5-MeOT was dose dependently antagonised by 
yohimbine and rauwolscine (fig. 2; IDs0 values were 3 and 4 mglkg, respectively). The 
effect of piperoxan was variable, at 10 mgkg an inhibition of 53% was reached. Other 
compounds that attenuated 5-MeOT-induced scratching were the serotonergic agonists 
8-OH-DPAT, MK 212, DO1 and quipazine; their IDso values are shown in table 2. 
Scratching was also attenuated by the 5-HT releasing compounds, fenfluramine and 
PCA (fig. 3). 
5-MeOT-induced hindlimb scratching could be inhibited by methiothepin, 
haloperidol, apomorphine, clonidine and morphine (IDs0 values were 0.2; 0.05; 0.07; 
0.015 and 0.6 mgkg, respectively), whereas ICS 205930, atropine and naloxone were 
only weakly active (IDs0 values: 10; > 2.2 and > 4.6 mgkg, respectively) and 
domperidone, mepyramine and methylatropine were inactive in doses up to 10 mglkg 
(table 2). Lower lip retraction was also seen after &OH-DPAT, penile erections after 
MK 212 and head shakes after DO1 and quipazine. The animals were sedated after 
methiothepin, apomorphine, haloperidol, clonidine and morphine 
6.3.3 Potentiation of 5-MeOT-induced hindlimb scratching 
Hindlimb scratching increased when the rats were treated with the 5-HT receptor 
antagonists xylarnidine (0.1 - 1.0 mgkg), mesulergine (0.022 - 0.22 mgkg), 
methysergide (0.1 - 1.0 mgkg), metergoline (0.1 - 1.0 mglkg), mianserin (0.046 - 0.46 
mgkg) or ritanserin (0.1 - 1.0 mgkg) 30 min before 5-MeOT was injected (table 3). 
This potentiation of hindlimb scratching was statistically significant and dose dependent 
for all these compounds. The 5-HT re-uptake blockers, fluvoxamine and indalpine, also 
increased 5-MeOT-induced hindlimb scratching (fig. 3). 
6.4 DISCUSSION 
In this study we found that S.C. injection of the 5-HT agonists 5-MeOT, 5-CT, 
bufotenine, 5-HT and tryptamine induced hindlimb scratching. Hindlimb scratching was 
not seen after injection of the 5-HT receptor agonists 8-OH-DPAT, MK 212, DO1 and 
quipazine. 5-MeOT, 5-CT, bufotenine, 5-HT and tryptamine all have high affinity for 
5-HTIA and 5-HTID receptors (Hoyer, 1989; table 4). 8-OH-DPAT has also high 
affinity for 5-HTIA receptors but hardly binds to 5-HTID receptors. As 8-OH-DPAT did 
not induce hindlimb scratching, 5-HTIA receptors are not likely to be involved in this 
response. It is thus attractive to suggest that hindlimb scratching mediated by 
serotonergic compounds is related to an agonistic effect of these compounds on 
5-HTID- or 5-HTID-like receptors. 5-HTID receptors have been found in the basal 
ganglia and the substantia nigra in bovine, pig and human brains (Heuring and Peroutka, 
1987; Waeber et al., 1988 a,b), whereas the same areas in the rat are rich in 5-HT,, 
receptors (Pazos and Palacios, 1985). Herrick-Davies and Titeler (1988), however, 
found a 5-HT receptor in the rat brain with a pharmacology similar to that of 
Table 4. Affinity of several 5-HT agonists used in this study for the different 5-HT receptor 
subtypes 









MK 2 1 2 ~ )  
Affinity values are from Hoyer, 1989. Values are calculated from Titeler et al., 1988. 2, Values 
are from Hoyer, 1988. 
the 5-HTID receptor detected in bovine brain by Heuring and Peroutka (1987). Thus it 
seems that both 5-HTID and 5-HTIB receptors may be present in the rat CNS. 
Serotonergically induced hindlimb scratching, however, seems to be mediated by a 
receptor system that is localised outside the blood-brain barrier. Hindlimb scratching 
could be induced by systemic but not i.c.v. injection of 5-MeOT. The 100 pglrat dose 
given i.c.v. is approximately equal to a dose of 0.5 mglkg. Such a dose, if given s.c., 
induces scratching. Furthennore, 5-MeOT-induced hindlimb scratching could be 
potentiated by xylarnidine, a compound that does not cross the blood-brain barrier 
(Fuller et al., 1986). In the periphery, 5-HTID- or 5-FITlD-like receptors might be 
present in the carotid vascular bed and be involved in the pathophysiology of migraine. 
GR 43175 and serotonin, compounds that do not cross the blood-brain barrier and 
which have a high affinity for 5-HTID receptors (Peroutka and McCarthy, 1989; Hoyer, 
1989), appear to be highly effective in suppressing acute migraine attacks (Saxena and 
Ferrari, 1989; Doenicke et al., 1988). 
Serotonergically mediated scratching is distinguished from peptide-induced 
scratching in rats by the site of action. Peptidergic scratching has only been seen after 
i.c.v. application of the compounds and is therefore centrally mediated (Van Wimersma 
Greidanus et al., 1985, 1987; Negri, 1986; Van Wimersma Greidanus and Maigret, 
1988). 
5-MeOT-induced hindlimb scratching was dose dependently inhibited by the a2 
adrenoceptor blockers yohimbine and rauwolscine. Both compounds have, besides their 
a2 blocking properties, high affinity for 5-HTID receptors (Hoyer, 1989). It is thus 
attractive to speculate that the effect of these compounds on hindlimb scratching is due 
to their 5-HTID antagonistic properties. However, a non specific effect of these 
compounds cannot be excluded since the a2-adrenoceptor blocker piperoxan also had an 
effect on hindlimb scratching. Both yohimbine and rauwolscine caused sedation at a 
dose of 4.6 mglkg, which might contribute to the inhibition of hindlimb scratching. 
Sedation may also be the best explanation for the inhibiting effect of haloperidol on 
hindlimb scratching since this compound hardly binds to 5-HTID receptors (Hoyer, 
1989) and an effect mediated by peripheral dopamine receptor blockade is unlikely 
since hindlimb scratching was not affected by domperidone, a dopamine receptor 
blocker that does not pass the blood brain barrier and does not cause sedation. The 
dopaminergic agonist apomorphine strongly and dose dependently inhibited 5-MeOT- 
induced hindlimb scratching. Both haloperidol and apomorphine caused sedation in the 
doses tested, as did morphine, clonidine, ICS 205930 and methiothepin. It is thus 
possible that serotonergic-mediated hindlimb scratching is very sensitive to sedation, 
independent of the underlying transmitter mechanisms. The observation that hindlimb 
scratching can be overruled by other behavioural disturbances might also be the cause 
of the biphasic effect of 5-HT, since at 10 mgtkg flat body posture and cyanosis were 
seen. The small response seen after tryptamine might also be caused by non-specific 
side effects (ptosis), but it should also be noted that, of the compounds tested, 
tryptarnine has the lowest affinity for 5-HTID receptors (table 4). 
5-MeOT-induced hindlimb scratching was dose dependently inhibited by the 
5-HTIA receptor selective agonist 8-OH-DPAT, the 5-HTlc receptor agonist MK 212 
and the mixed 5-HTlc 15-HT2 receptor agonists DO1 and quipazine. We have seen 
before that lower lip retraction induced in rats by activation of central 5-HTIA receptors 
can be attenuated by concomitant activation of 5-HTlc and/or 5-HT2 receptors 
(Berendsen et al., 1989) and that penile erections induced by activation of central 
5-HTlc receptors can be attenuated by concomitant activation of 5-HTIA or 5-HT2 
receptors (Berendsen et al., 1990). A similar functional influence may take place 
between 5-HTlD- or 5-HTID-like receptors and 5-HTIA, 5-HTlc and 5-HT2 receptor 
subtype-mediated events. It should be noted however, that a compound like 5-CT, which 
has high affinity for both 5-HTIA and 5-HTlD binding sites, induced lower lip 
retraction, be it weakly, and hindlimb scratching, whereas 8-OH-DPAT strongly 
inhibited hindlimb scratching. The efficacies of the compounds for 5-HTIA and 5-HTID 
receptors might be very important in this respect. 
The effects of the indirect 5-HT receptor agonists are puzzling. The 5-HT 
releasing compounds fenfluramine and PCA attenuated hindlimb scratching whereas the 
5-HT-re-uptake inhibitors indalpine and fluvoxamine potentiated hindlimb scratching. 
In both cases the synaptic availability of 5-HT is increased, and both 5-HT-releasing 
compounds and 5-HT-re-uptake inhibitors induce 5-HTlc receptor mediated penile 
erections (Berendsen and Broekkamp, 1987; Berendsen et al., 1990). As yet we do not 
have an explanation for this difference. 
5-MeOT-induced hindlimb scratching was potentiated by the 5-HTlc/5-HT2 
receptor antagonists xylamidine, metergoline, methysergide, mesulergine, mianserin and 
ritanserin. The potentiating effect of these 5-HT receptor antagonists cannot simply be 
explained by a facilitating effect due to blockade of other 5-HT receptor subtypes, 
because metergoline and methysergide have a high affinity for 5-HTlc, 5-HT2 and 
5-HTID receptors (Hoyer, 1989). These compounds may, however, act as agonists at the 
receptor mediating hindlimb scratching. In line with this idea are the findings of Saxena 
(1974) and Humphrey et al. (1990) that methysergide acts as an agonist at peripheral 
5-HT receptors by selectively causing carotid vasoconstriction, an effect also caused by 
5-HT. The 5-HT receptor antagonist methiothepin inhibited 5-MeOT-induced hindlimb 
scratching. This compound has substantial 5-HTlD receptor antagonistic properties 
(Hoyer and Middlemiss, 1989) but is also a strong dopamine receptor antagonist and 
causes sedation. It is not clear which of these properties was responsible for the 
attenuating effect on hindlimb scratching. Hindlimb scratching induced by systemic 
injection of serotonergic compounds seems to be mediated by 5-HTID-like receptors 
outside the blood-brain barrier. Some of the synaptic events involved remain to be 
clarified. 
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